Search Results - "Hagelstein, Ilona"

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition by Nelde, Annika, Bilich, Tatjana, Heitmann, Jonas S., Maringer, Yacine, Salih, Helmut R., Roerden, Malte, Lübke, Maren, Bauer, Jens, Rieth, Jonas, Wacker, Marcel, Peter, Andreas, Hörber, Sebastian, Traenkle, Bjoern, Kaiser, Philipp D., Rothbauer, Ulrich, Becker, Matthias, Junker, Daniel, Krause, Gérard, Strengert, Monika, Schneiderhan-Marra, Nicole, Templin, Markus F., Joos, Thomas O., Kowalewski, Daniel J., Stos-Zweifel, Vlatka, Fehr, Michael, Rabsteyn, Armin, Mirakaj, Valbona, Karbach, Julia, Jäger, Elke, Graf, Michael, Gruber, Lena-Christin, Rachfalski, David, Preuß, Beate, Hagelstein, Ilona, Märklin, Melanie, Bakchoul, Tamam, Gouttefangeas, Cécile, Kohlbacher, Oliver, Klein, Reinhild, Stevanović, Stefan, Rammensee, Hans-Georg, Walz, Juliane S.

“…T cell immunity is central for the control of viral infections. To characterize T cell immunity, but also for the development of vaccines, identification of…”
Get full text

An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer by Lutz, Martina S, Wang, Kevin, Jung, Gundram, Salih, Helmut R, Hagelstein, Ilona

“…Pancreatic cancer is a highly lethal disease with limited treatment options. Hence, there is a considerable medical need for novel treatment strategies…”
Get full text

The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas by Holzmayer, Samuel J, Liebel, Kai, Hagelstein, Ilona, Salih, Helmut R, Märklin, Melanie

“…Sarcomas are rare and heterogeneous malignancies that are difficult to treat. Approximately 50% of patients diagnosed with sarcoma develop metastatic disease…”
Get full text

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma by Hagelstein, Ilona, Engel, Monika, Hinterleitner, Clemens, Manz, Timo, Märklin, Melanie, Jung, Gundram, Salih, Helmut R., Zekri, Latifa

“…Natural killer (NK) cells largely contribute to antibody-dependent cellular cytotoxicity (ADCC), a central factor for success of monoclonal antibodies (mAbs)…”
Get full text

Targeting CD276 for T cell-based immunotherapy of breast cancer by Hagelstein, Ilona, Wessling, Laura, Rochwarger, Alexander, Zekri, Latifa, Klimovich, Boris, Tegeler, Christian M, Jung, Gundram, Schürch, Christian M, Salih, Helmut R, Lutz, Martina S

“…Breast cancer (BC) is the most common malignancy in women. Immunotherapy has revolutionized treatment options in many malignancies, and the introduction of…”
Get full text

Identification of CD318 (CDCP1) as novel prognostic marker in AML by Heitmann, Jonas S., Hagelstein, Ilona, Hinterleitner, Clemens, Roerden, Malte, Jung, Gundram, Salih, Helmut R., Märklin, Melanie, Kauer, Joseph

“…Genetic and morphological markers are well-established prognostic factors in acute myeloid leukemia (AML). However, further reliable markers are urgently…”
Get full text

CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation by Märklin, Melanie, Hagelstein, Ilona, Hinterleitner, Clemens, Salih, Helmut R., Kauer, Joseph, Heitmann, Jonas S.

“…Several genetic and molecular markers are general predictors of outcome in acute myeloid leukemia (AML), but only few are predictive of outcomes after…”
Get full text

Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer by Kaidun, Polina, Holzmayer, Samuel J, Greiner, Sarah M, Seller, Anna, Tegeler, Christian M, Hagelstein, Ilona, Mauermann, Jonas, Engler, Tobias, Koch, André, Hartkopf, Andreas D, Salih, Helmut R, Märklin, Melanie

“…Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with a poor response rate to conventional systemic treatment and…”
Get full text

Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome by Seller, Anna, Tegeler, Christian M, Mauermann, Jonas, Schreiber, Tatjana, Hagelstein, Ilona, Liebel, Kai, Koch, André, Heitmann, Jonas S, Greiner, Sarah M, Hayn, Clara, Dannehl, Dominik, Engler, Tobias, Hartkopf, Andreas D, Hahn, Markus, Brucker, Sara Y, Salih, Helmut R, Märklin, Melanie

“…Ligands of the natural killer group 2D (NKG2DL) family are expressed on malignant cells and are usually absent from healthy tissues. Recognition of NKG2DLs…”
Get full text

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer by Zekri, Latifa, Vogt, Fabian, Osburg, Lukas, Müller, Stefanie, Kauer, Joseph, Manz, Timo, Pflügler, Martin, Maurer, Andreas, Heitmann, Jonas S, Hagelstein, Ilona, Märklin, Melanie, Hörner, Sebastian, Todenhöfer, Tilmann, Calaminus, Carsten, Stenzl, Arnulf, Pichler, Bernd, la Fougère, Christian, Schneider, Marc A, Rammensee, Hans‐Georg, Zender, Lars, Sipos, Bence, Salih, Helmut R, Jung, Gundram

“…The prostate‐specific membrane antigen (PSMA) has been demonstrated in numerous studies to be expressed specifically on prostate carcinoma cells and on the…”
Get full text

Identification of CD105 (endoglin) as novel risk marker in CLL by Greiner, Sarah M., Märklin, Melanie, Holzmayer, Samuel, Kaban, Kübra, Meyer, Sophie, Hinterleitner, Clemens, Tandler, Claudia, Hagelstein, Ilona, Jung, Gundram, Salih, Helmut R., Heitmann, Jonas S., Kauer, Joseph

“…Several genetic and clinical markers are established as prognostic factors in chronic lymphocytic leukemia (CLL). However, additional markers are needed for…”
Get full text

1353 An Fc-optimized B7-H3-targeting antibody for treatment of ovarian cancer by Hagelstein, Ilona, Wang, Kevin, Jung, Gundram, Salih, Helmut R, Lutz, Martina S

“…BackgroundOvarian cancer remains the most lethal gynecologic malignancy to date and thus represents a substantial health challenge. The introduction of…”
Get full text

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity by Rothfelder, Kathrin, Hagelstein, Ilona, Roerden, Malte, Blumenstock, Gunnar, Hofmann, Martin, Nuebling, Tina, Jung, Gundram, Salih, Helmut Rainer, Dörfel, Daniela

“…OX40 and its ligand are members of the TNF/TNF receptor superfamily, which includes various molecules influencing cellular signaling and function of both tumor…”
Get full text

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody by Stefańczyk, Sylwia A., Hagelstein, Ilona, Lutz, Martina S., Müller, Stefanie, Holzmayer, Samuel J., Jarjour, Grace, Zekri, Latifa, Heitmann, Jonas S., Salih, Helmut R., Märklin, Melanie

“…Acute myeloid leukemia (AML) remains a therapeutic challenge despite recent therapeutic advances. Although monoclonal antibodies (mAbs) engaging natural killer…”
Get full text

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas by Hagelstein, Ilona, Lutz, Martina S, Schmidt, Moritz, Heitmann, Jonas S, Malenke, Elke, Zhou, Yanjun, Clar, Kim L, Kopp, Hans-Georg, Jung, Gundram, Salih, Helmut R, Märklin, Melanie, Hinterleitner, Clemens

“…Soft tissue sarcoma (STS) constitutes a rare group of heterogeneous malignancies. Effective treatment options for most subtypes of STS are still limited. As a…”
Get full text

1459 Association with stemness and functional role of immunoreceptor NKG2D expression in acute myeloid leukemia by Hagelstein, Ilona, Stefanczyk, Sylwia A, Clar, Kim L, Rothfelder, Kathrin, Rieth, Jonas, Heitmann, Jonas S, Salih, Helmut R

“…BackgroundThe activating immunoreceptor NKG2D is expressed on cytotoxic lymphocytes (CTL) like NK cells, CD8+ cytotoxic T cells and γδ T cells. It potently…”
Get full text

1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer by Lutz, Martina S, Weßling, Laura, Zekri, Latifa, Tegeler, Christian M, Hagelstein, Ilona, Jung, Gundram, Salih, Helmut R

“…BackgroundInvasive breast cancer is the most common malignant disease in women worldwide. HER2-targeting antibodies like Trastuzumab have achieved notable…”
Get full text

1390 A Fc-optimized B7-H3 antibody for induction of NK cell reactivity against acute myeloid leukemia by Stefanczyk, Sylwia A, Hagelstein, Ilona, Lutz, Martina S, Müller, Stefanie, Zekri, Latifa, Heitmann, Jonas S, Salih, Helmut R, Märklin, Melanie

“…BackgroundAcute myeloid leukemia (AML) is the most frequent acute leukemia in adults. Although treatment options of AML have improved during the last decade,…”
Get full text

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia by Märklin, Melanie, Hagelstein, Ilona, Koerner, Samuel P, Rothfelder, Kathrin, Pfluegler, Martin S, Schumacher, Andreas, Grosse-Hovest, Ludger, Jung, Gundram, Salih, Helmut R

“…Monoclonal antibodies (mAbs) mediate their effects in great part by inducing ADCC of NK cells, and multiple efforts aim to increase this function by…”
Get full text

An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers by Zekri, Latifa, Lutz, Martina, Prakash, Nisha, Manz, Timo, Klimovich, Boris, Mueller, Stefanie, Hoerner, Sebastian, Hagelstein, Ilona, Engel, Monika, Chashchina, Anna, Pfluegler, Martin, Heitmann, Jonas S., Jung, Gundram, Salih, Helmut R.

“…T cell-based immunotherapy has revolutionized oncological treatment. However, many patients do not respond to treatment, and long-term remissions remain rare,…”
Get full text